Patent details

Basic Information

Publication number:

LUC00160

Type:

SPC

SPC Type:

Medical

Basic Patent Number:

EP097935464

Legal Status:

Inactive

Application number:

LUC00160

First applicant's nationality:

Procedural language:

French

Marketing Authorization

Marketing Authorization Number:

EU/1/19/1414

Marketing Authorization Type:

Marketing Authorization Date:

15/01/2020

Marketing Authorization Status:

Accepted

Marketing Authorization Country:

Luxembourg (LU)

Dates

Filing date:

18/06/2020

First Marketing Authorization date:

15/01/2020

Grant date:

06/07/2021

Activation date:

Publication date:

19/06/2020

Lapsed date:

Expiration date:

Renunciation date:

Revocation date:

Annulment date:

Basic SPC Expiration:

21/12/2034

SPC Extension Expiration:

21/12/2034

Rejection date:

Withdrawal date:

Owner

From:

18/06/2020

 

 

Name:

Novartis AG

Address:

Lichtstrasse 35, 4056 Basel, Switzerland (CH)

Agent

Name:

OFFICE FREYLINGER S.A.

From:

18/06/2020

Address:

Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)

To:

Publication

Bulletin

1

Bulletin Heading:

SPC1

Bulletin edition number:

2020/08

Publication date:

13/07/2020

Description:

Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:

SPC2

Bulletin edition number:

2021/09

Publication date:

03/08/2021

Description:

Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:

31/12/2029

Annual Fee Number:

21

Annual Fee Amount:

410 Euro

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages
19/06/2020	Publication	1
06/07/2021	Certificate	1
18/06/2020	General Document	11
06/07/2021	Outgoing Correspondence	1
18/06/2020	Application Form	4
18/06/2020	General Document	55
19/06/2020	Outgoing Correspondence	1
06/07/2021	Publication	1
18/06/2020	General Document	3